Virchow Healthcare Private Limited

Virchow Healthcare Private Limited (VHPL) is a privately held pharmaceutical company established on November 20, 2007, in Mumbai, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24230MH2007PTC176048. VHPL operates as a subsidiary within the Virchow Group, a conglomerate with over 30 years of experience in the pharmaceutical industry. The group boasts an annual turnover exceeding $1 billion and employs over 5,000 individuals across its various entities.

VHPL's authorized and paid-up capital stands at ₹2.00 crore (approximately $250,000 USD). The company employs a dedicated team of professionals, with a focus on delivering advanced biological and pharmaceutical formulations to emerging markets. Its product portfolio includes advanced wound care, orthopedics, anti-thrombotics, oncology, blood and plasma products, anti-retrovirals, cardio-diabetics, probiotics, ophthalmics, cephalosporins, and nutraceuticals.

VHPL operates manufacturing facilities within the Virchow Group, which encompasses 11 manufacturing sites. These facilities are strategically located to serve both domestic and international markets. The group's manufacturing capabilities include the production of critical high-purity active pharmaceutical ingredients (APIs) and intermediates, with Virchow Labs being recognized as the world's largest producer of Sulfamethoxazole and Trimethoprim.

The leadership team at VHPL comprises:

• Kamal Kishore Ved Prakash Babbar: Managing Director, appointed on November 20, 2007.

• Narayana Reddy Mundla: Director, appointed on November 20, 2007.

• Hemanth Nandigala: Director, appointed on November 20, 2007.

VHPL has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's regulatory affairs team is equipped to work in synergy with both marketing and manufacturing teams, ensuring compliance with international standards. This includes processes from product selection to post-launch activities, with a focus on staying abreast of current and upcoming regulatory trends.

VHPL has expanded its reach to emerging markets in Africa, Latin America, and Southeast Asia. The company's regulatory approvals include WHO-GMP, PIC/S (Ukraine), PPB (Kenya), NAFDAC (Nigeria), NDA (Uganda), and FDA (Ghana), facilitating access to these regions.

VHPL's geographic strategy involves diversification across multiple regions, including South-East Asia, Africa, Russia – CIS, and Latin & South America. This approach mitigates concentration risk and aligns with the company's strategic direction to provide affordable healthcare solutions globally.

VHPL's regulatory affairs team is equipped to work in synergy with both marketing and manufacturing teams, ensuring compliance with international standards. This includes processes from product selection to post-launch activities, with a focus on staying abreast of current and upcoming regulatory trends.

VHPL has obtained WHO-GMP certification, facilitating access to various international markets. The company's regulatory affairs team ensures compliance with international standards, including WHO-GMP, to meet the stringent requirements of global markets.

VHPL holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers. The company also possesses export No Objection Certificates (NOCs), enabling it to export pharmaceutical products to various international markets.

As of March 28, 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to VHPL. The company's regulatory affairs team maintains a proactive approach to ensure compliance with international standards and promptly addresses any regulatory concerns.

VHPL operates in a competitive landscape with several key players in the pharmaceutical industry. The company's focus on emerging markets and its diverse product portfolio, including advanced wound care, orthopedics, and oncology, position it favorably against competitors. VHPL's commitment to quality and regulatory compliance further strengthens its competitive edge.

VHPL's key differentiators include its extensive product portfolio covering various therapeutic segments, a strong presence in over 50 countries, and a commitment to meeting stringent regulatory standards. The company's affiliation with the Virchow Group, a conglomerate with over 30 years of experience and an annual turnover exceeding $1 billion, provides additional strength and credibility.

VHPL's current strategic direction focuses on expanding its presence in emerging markets, diversifying its product offerings, and maintaining high-quality standards. The company's future outlook includes leveraging its regulatory approvals and manufacturing capabilities to enhance its position in the global pharmaceutical market.

VHPL has demonstrated a consistent track record in pharmaceutical manufacturing, with a focus on quality and regulatory compliance. The company's export volume and consistency are supported by its regulatory approvals and strategic partnerships, indicating reliability in meeting international standards.

Importers should verify the following certifications when considering VHPL as a supplier:

• WHO-GMP Certification: Ensures compliance with World Health Organization Good Manufacturing Practices.

• EU GMP Certification: Confirms adherence to European Union Good Manufacturing Practices.

• FDA Approval: Indicates compliance with U.S. Food and Drug Administration standards.

• ISO Certifications: Demonstrate adherence to international quality management standards.

These certifications can typically be verified through the respective regulatory bodies or VHPL's official communications.

When conducting due diligence on VHPL, consider the following steps:

• Verify Regulatory Certifications: Confirm WHO-GMP, EU GMP, FDA, and ISO certifications.

• Review Financial Statements: Assess the company's financial health through audited financial statements.

• Evaluate Manufacturing Facilities: Inspect facilities for compliance with international standards.

• Assess Product Portfolio: Ensure the product range aligns with market needs and quality expectations.

• Check Compliance History: Review any past regulatory actions or compliance issues.

Red flags to watch for include expired certifications, unresolved regulatory issues, and discrepancies in financial reporting. Recommended pre-order checks involve verifying the authenticity of certifications and conducting on-site inspections of manufacturing facilities.